CN103768294A - Medical application of colocasia tonoimo nakia and stem leaves thereof in preventing and treating diabetes - Google Patents
Medical application of colocasia tonoimo nakia and stem leaves thereof in preventing and treating diabetes Download PDFInfo
- Publication number
- CN103768294A CN103768294A CN201310474691.4A CN201310474691A CN103768294A CN 103768294 A CN103768294 A CN 103768294A CN 201310474691 A CN201310474691 A CN 201310474691A CN 103768294 A CN103768294 A CN 103768294A
- Authority
- CN
- China
- Prior art keywords
- stem
- purple taro
- leaf
- extract
- taro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 25
- 241000788499 Colocasia tonoimo Species 0.000 title abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 28
- 244000205754 Colocasia esculenta Species 0.000 claims description 89
- 235000006481 Colocasia esculenta Nutrition 0.000 claims description 89
- 238000002360 preparation method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- 238000005516 engineering process Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 238000009455 aseptic packaging Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 50
- 210000004369 blood Anatomy 0.000 abstract description 50
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 46
- 239000008103 glucose Substances 0.000 abstract description 46
- 230000000694 effects Effects 0.000 abstract description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 15
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 14
- 235000012000 cholesterol Nutrition 0.000 abstract description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract description 4
- 230000000291 postprandial effect Effects 0.000 abstract description 3
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 7
- 230000002218 hypoglycaemic effect Effects 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 229960004329 metformin hydrochloride Drugs 0.000 description 7
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000011321 prophylaxis Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 235000010208 anthocyanin Nutrition 0.000 description 4
- 229930002877 anthocyanin Natural products 0.000 description 4
- 239000004410 anthocyanin Substances 0.000 description 4
- 150000004636 anthocyanins Chemical class 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- -1 60 °C following dry Substances 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010054196 Affect lability Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000006620 Calla palustris Species 0.000 description 1
- 235000004012 Calla palustris Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 150000008131 glucosides Chemical group 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses application of colocasia tonoimo nakia and stem leaves thereof in preparing medicine for preventing and treating diabetes, and relates to the second medical application of the colocasia tonoimo nakia and the stem leaves thereof. The colocasia tonoimo nakia and the stem leaves thereof have the effects of preventing and treating type 2 diabetes, and the functions of reducing fasting blood glucose and postprandial blood sugar for type 2 diabetes patients, and also have the functions of reducing blood fat and total cholesterol, and increasing high-density lipoprotein. The medicine for preventing and treating diabetes is prepared by utilizing the functions of the colocasia tonoimo nakia and the stem leaves for reducing blood sugar, improving glucose tolerance, regulating blood fat, and protecting and repairing damaged pancreas islet.
Description
Technical field
The invention discloses the medical application of purple taro in prophylactic treatment diabetes, be further to provide purple taro and stem and leaf thereof the purposes in preparation prophylactic treatment diabetes medicament, relate to the second medical applications of purple taro and stem and leaf thereof, belong to medical science pharmaceutical technology field.
Background technology
The purple taro the present invention relates to means (Colocasia tonoimo Nakai), and Araeceae taro platymiscium has another name called water arum, Rhizoma Colocasiae antiquori, southeast taro, the wide dish of tiger.Acrid in the mouth; Cold in nature, there is mass dissipating and swelling eliminating; Dispel the wind effect of removing toxic substances, main acute mastitis; Innominate toxic swelling; Urticaria; Furuncle; Aphtha; Burn and scald etc.
The research report of purple taro is less at present, is mainly used in foodstuff, and it is the one of taro class, has good health-care effect, is a kind of food of health, have the wind of food taro, but taro has few poison at south China, must be after treatment edible.From threpsology's angle analysis, taro rich in proteins, fat, carotene and various cellulose, and the composition such as calcium ferrophosphorus, be applied to various dish, taro juice as purple in Flos Osmanthi Fragrantis, purple taro pudding, purple taro egg tart, purple taro salad, purple taro morrhua ball and beverage, dessert, cold dish, until Hot dishes enters dining table one after another, are welcome by a person sponging on an aristocrat quite.Simultaneously the extraction of substance of purple taro can be used as pigment that natural pigment substitutes synthetic and is applied to and improves food color aspect.
The report of purple taro chemical constitution study aspect is few; Wang Ruilan contains abundant nutritional labeling point out purple taro in " antioxidant activity of purple taro anthocyanin and stability study thereof " in; and anthocyanin is its main present-color material. anthocyanin belongs to flavonoids; in recent years; some researchs show, anthocyanin can enter and in body, present the various biological activity such as antioxidation, sudden change, antitumor, prevention and cure of cardiovascular disease, the liver protecting function with complete glucosides form.
Summary of the invention
The medical application of purple taro in prophylactic treatment diabetes provided by the invention, provides the new medical science pharmaceutical usage of purple taro and stem and leaf thereof, can be used for the medicine of preparation prevention and treatment diabetes.
purple taro disclosed by the invention and the medical application of stem and leaf in prophylactic treatment diabetes thereof, is characterized in that:
Purple taro and stem and leaf thereof have preventive and therapeutic action to type 2 diabetes mellitus, have the effect that reduces fasting glucose and post-prandial glycemia for type 2 diabetes mellitus patient, and have the blood fat of reduction, T-CHOL, the effect that improves high density lipoprotein.
the preparation method of purple taro disclosed by the invention and stem and leaf extract thereof, is characterized in that:
Get purple taro or its stem and leaf removes mud
,add 2-10 times of water gaging, boil; After ultra high temperature short time sterilization, adopt aseptic packaging technology to pack.
two of the preparation method of purple taro disclosed by the invention and stem and leaf extract thereof, is characterized in that:
Get purple taro or its stem and leaf removes mud
,add 5-30 times of water gaging or organic solvent, decoct or heating or reflux (1-4 time, each 0.1-3 hour), get extracting solution reclaim under reduced pressure; Also can be further refining by methods such as precipitate with ethanol, obtain extract, make various preparations.
The effective ingredient containing in the medicine that contains purple taro extract of the present invention is the compositions such as polysaccharide and saponins.
Drug effect compositions of the present invention the pharmaceutical composition that contains one or more pharmaceutically acceptable carriers or excipient.
The present invention can with purple taro or its stem and leaf be single or the form of compositions is applied to the patient for the treatment of diabetes by Oral administration.Also all have medicine, food, the healthy functions food of the disease such as prophylactic treatment type 2 diabetes mellitus and other cardiovascular can to make beverage, cake, canned food, Semen Glycines powder, electuary etc.
Dose of the present invention can be according to route of administration and combined situation, the variations such as patient age, body weight, disease and ill degree, and the daily dose of purple taro and stem and leaf thereof is 50-300g/ days.
Clinically the consumption 30-300g/ every day of the oral purple taro of average man or its stem and leaf, their extract consumption is 0.5-9g, every day twice, takes and within 20-30 days, can be used for prevention and treatment diabetes and complication thereof.
The present invention applies the extract of purple taro and stem and leaf thereof and processes respectively type 2 diabetes mellitus mice, the extract that found that purple taro and stem and leaf thereof obviously improves fasting glucose and carbohydrate tolerance, can reduce alloxan induction insulin resistant sugar cholesterol and the content of triglyceride of hyperlipoidemia rat.And there is the blood fat, T-CHOL of reduction, the effect that improves high density lipoprotein.Alloxan is caused to diabetic mice hyperglycemia has obvious hypoglycemic activity.Therefore, purple taro and stem and leaf thereof are having considerable development and application to be worth aspect prevention and treatment diabetes.
good effect of the present invention is:
Disclose first purple taro and stem and leaf thereof type 2 diabetes mellitus is had to prophylactic treatment effect, there is the effect that reduces fasting glucose and post-prandial glycemia for type 2 diabetes mellitus patient, and there is the blood fat of reduction, T-CHOL, the effect that improves high density lipoprotein.Utilize the effect of blood fat and protection and the impaired islets of langerhans of reparation that there is blood sugar lowering, improves glucose tolerance, regulates of purple taro and stem and leaf thereof to make medicine, for prevention and treatment diabetes.
The specific embodiment
embodiment 1
Get purple taro stem and leaf and remove mud
,approximately add 2 times of water gagings, boil, after ultra high temperature short time sterilization, adopt aseptic packaging technology to pack.
embodiment 2:
Get purple taro and remove mud
,add 8 times of water gagings, boil, make slurry with refiner; After ultra high temperature short time sterilization, adopt aseptic packaging technology to pack.
embodiment 3
Get purple taro and stem and leaf thereof and remove mud
,add 10 times of water gagings, boil, filtering and concentrating, after ultra high temperature short time sterilization, adopts aseptic packaging technology to pack.
embodiment 4
Get purple taro stem and leaf and remove mud
,add 5 times of water gagings to decoct 3 times hours, each 0.1 hour, collecting decoction, concentrated, dry, to obtain final product.
embodiment 5
Get purple taro and remove mud, add 20 times of amount 50% ethanol, reflux 2 times, each 0.5 hour.Merge extractive liquid,, reclaims ethanol, and drying under reduced pressure, obtains purple taro extract.
embodiment 6
Get purple taro and stem and leaf thereof and remove mud, add 30 times of amount 50% ethanol, reflux 2 times, each 1.0 hours.Merge extractive liquid,, reclaims ethanol, and drying under reduced pressure, obtains purple taro extract.
embodiment 7
Get purple taro and add 25 times of water gagings, decoct each 2 hours 1 time.Collecting decoction, concentrated, dry, obtain purple taro stem and leaf extract.
embodiment 8
Get the extract obtained 300g of embodiment 1 ~ embodiment 7 and add appropriate amount of starch, mix, 60 ℃ following dry, encapsulated 1000, obtains this product capsule preparations.This project meets the relevant requirements of 2000 editions capsule projects of Pharmacopoeia of People's Republic of China.
embodiment 9
Get the extract obtained 500g of embodiment 1 ~ embodiment 7 and add appropriate amount of starch, lubricant, mix, 60 ℃ following dry, and tabletting, obtains 1000.This project meets the relevant requirements of 2000 editions tablet projects of Pharmacopoeia of People's Republic of China.
embodiment 10
Get the extract obtained 800g of embodiment 11 ~ embodiment 7 and add appropriate amount of starch, mix, 60 ℃ following dry, granulates, and obtains 1000 bags of granules.This project meets the relevant requirements of 2000 editions granule projects of Pharmacopoeia of People's Republic of China.
show the medical science effect of purple taro by following experiment:
experimental example 1
the assay of the purple taro extract of the present invention polysaccharide
1. the purple taro extract of experiment material the present invention, gets purple taro water extraction, concentrates and get final product.
2. method and result
The preparation of glucose reference substance solution
Get dry glucose 8mg, accurately weighed, be dissolved in water and move in 100mL volumetric flask, add water to scale, shake up, be made into the solution of 80 μ g/mL, for subsequent use.
Sample solution preparation
Sample thief 0.1g, accurately weighed, add in 100mL volumetric flask and be settled to scale, shake up, for subsequent use.
Assay method
Get the each 1.0mL of reference substance and test sample, put in tool plug test tube, adding distil water is to 2mL, add respectively developer 5.5 mL, boiling water bath 4min, according to spectrophotography (Chinese Pharmacopoeia appendix VA in 2010), at wavelength 625 nm places, measure trap value, calculate content.
3. result and discussion
The purple taro stem and leaf extract of table 1 total sugar content measurement result
The purple taro bulb of table 2 extract total sugar content measurement result
Purple taro sample determination total sugar content, with glucose meter, stem and leaf is containing total sugar 5.15%, and bulb total sugar is containing 9.64%.
experimental example 2
the effect of purple taro (stem and leaf and the bulb) extract of the present invention to type 2 diabetes mellitus mice
Experiment material
(1)animal: Kunming mouse, male, body weight 19～22g and 22-25, purchased from animal housing of Norman Bethune Medical University; The quality certification number is SCXK-(Ji) 2008-0005;
(2) medicine: purple taro stem and leaf extract is provided by Jilin Academy of Chinese Medicine Sciences.Blood sugar kit is by raw providing in Beijing, and lot number is respectively 201206 and 201107112671.
(3) dosage setting: sample proposes people with dosage 30g crude drug/70kg, purple taro stem and leaf extract dosage is 40,2.0,1.0g/kg.
Experimental technique
Get healthy male ICR mouse some, normal feedstuff adaptability is raised one week, get at random 10 as blank group, all the other mices are given high lipid food (Adeps Sus domestica 1kg, sucrose 1.5kg, yolk powder 1.5kg, casein 0.5kg, cholesterol 120g, sodium cholate 20g, calcium bicarbonate 60g, stone powder 40g) raising surrounding, mice fasting be can't help after water 12 h, the front fresh preparation for 50mg/kgBW(of iv injection alloxan) modeling, continue with after fed with high surrounding, measure fasting glucose, blood glucose value higher than the mice of 7.8 mmol/L as type 2 diabetes mellitus modeling success mice.Divide 8 groups at random by successful modeling mice, 10 every group.Purple taro extract high dose 4g/kg, dosage 2g/kg in purple taro extract, normal group and model group are given isopyknic placebo.Being unified in every morning is administered once, successive administration 4 weeks.
After administration 4 weeks, respectively organize mouse assay fasting glucose, carbohydrate tolerance, mice serum cholesterol TC, triglyceride TG level.
Data statistics
Data result represents with mean+SD.Carry out statistical analysis with SPSS17.0 software, carry out deal with data with ANOVA variance analysis, * represent and significantly (P < 0.05) of model group comparing difference, # represents and significantly (P < 0.05) of normal group comparing difference.
Experimental result
After administration 4 weeks, the result of mice fasting blood glucose level is as table 3.Compared with model group, each administration group blood glucose all has obvious decline, and wherein, purple taro extract high dose group blood glucose declines to some extent, compares with model group, has downward trend.Therefore, purple taro extract all has the effect of blood sugar lowering trend to type 2 diabetes mellitus mice.
The impact of the purple taro extract of table 3 on insulin damage hyperglycemia model mice fasting glucose (
± S, n=10)
Table 4 on alloxan induction insulin resistant sugar hyperlipoidemia rat carbohydrate tolerance impact (
± S, n=10)
Note: with relatively * P<0.05 of model control group
From table 4, blood glucose value when model control group 0,0.5,2h, apparently higher than blank group, has significant difference, shows that hyperglycemia model sets up.Purple taro extract high dose carbohydrate tolerance has notable difference compared with model control group.Illustrate that purple taro extract can improve the resistance to sugar amount of type 2 diabetes mellitus mice.
The purple taro extract of table 5 on alloxan induction insulin resistant sugar hyperlipoidemia rat blood sugar area under curve impact (
± S, n=10)
Note: with relatively * P<0.05 of model control group
From table 5, model control group to glucose sugar after 0-2 hours blood glucose area under curve apparently higher than blank group, have significant difference.Purple taro extract high dose group has significant difference compared with model group.Illustrate purple taro extract can reduce alloxan induction insulin resistant sugar hyperlipoidemia rat blood sugar area under curve.
Table 6 blood-sugar reducing tea on alloxan induction insulin resistant sugar hyperlipoidemia rat cholesterol and triglyceride impact (
± S, n=10)
Note: with relatively * P<0.05. of model control group
From table 6, the cholesterol and triglyceride content of model control group, apparently higher than Normal group, has significant difference, shows the establishment of rat hyperlipoidemia.Purple taro is extracted object height, middle dosage cholesterol level is starkly lower than model control group, has significant difference.The high, medium and low dosage group of purple taro extract content of triglyceride is starkly lower than model control group, has significant difference.Show purple taro extract can reduce alloxan induction insulin resistant sugar cholesterol and the content of triglyceride of hyperlipoidemia rat.
experimental example 3
the purple taro stem and leaf extract of the present invention causes the impact of diabetic mice hyperglycemia on alloxan
experiment material
(1)animal: Kunming mouse, male, body weight 19～22g and 22-25, purchased from animal housing of Norman Bethune Medical University; The quality certification number is SCXK-(Ji) 2008-0005;
(2) medicine: purple taro stem and leaf extract is provided by Jilin Academy of Chinese Medicine Sciences.Metformin hydrochloride tablet is produced by Beijing JingFeng Pharmaceutical Co., Ltd.Lot number 20100718, blood sugar kit is by raw providing in Beijing, and lot number is respectively 201206 and 201107112671.
(3) dosage setting: sample proposes people with dosage 30g crude drug/70kg, purple taro stem and leaf extract dosage is 2.0,1.0,0.5g/kg; Metformin hydrochloride tablet is got the dose,equivalent 0.26g/kg group of people's consumption of 2 times.
(4) medicine preparation: press per kilogram 20 ml volumes preparations.
experimental technique and result
Get 120 of mices, be divided at random 6 groups, be respectively blank group, model control group, positive control metformin group 0.26g/kg, purple taro stem and leaf extract is high, medium and low 2.0,1.0,0.5g/kg group, tail vein injection alloxan 80mg/kg/10ml, after 72 hours, eye socket is got blood, pick hypoglycemia value animal, evenly divide into groups by blood glucose value, the results are shown in Table 7.
Each group blood glucose value (mmol/L) after table 7 modeling type
| Group | Number of animals | Dosage g/kg | Blood glucose value |
| Blank group | 10 | ? | 3.96±0.898 |
| Model control group | 10 | ? | 19.84±10.08 △△△ |
| Metformin hydrochloride tablet | 10 | 0.26 | 19.43±10.15 △△△ |
| Stem and leaf high dose | 10 | 2.0 | 18.78±9.79 △△△ |
| Dosage in stem and leaf | 10 | 1.0 | 19.84±11.09 △△△ |
| Stem and leaf low dosage | 10 | 0.5 | 19.57±6.63 △△△ |
Note: △ △ △ and the comparison of blank group, p<0.001
With the comparison of blank group, model is set up, and gets and makes model mouse, and each group is pressed the administration respectively of 20ml/kg volume, and blank and model group gavage equal-volume distilled water.Each group successive administration 10 days, hungry mice 16 hours before last administration, after last administration 40 minutes, pluck eyeball of mouse and get blood, survey blood glucose by glucose oxidase method with blood sugar kit.The results are shown in Table 8
Each group blood glucose value (mmol/L) after table 8 administration
| Group | Number of animals | Dosage g/kg | Blood glucose value |
| Blank group | 10 | ? | 8.67±1.76 |
| Model control group | 10 | ? | 21.08±0.892△△△ |
| Metformin hydrochloride tablet | 10 | 0.26 | 13.08± 8.59﹡﹡ |
| Stem and leaf high dose | 10 | 2.0 | 15.61±5.82﹡﹡ |
| Dosage in stem and leaf | 10 | 1.0 | 16.92±8.83﹡ |
| Stem and leaf low dosage | 10 | 0.5 | 23.07±5.02 |
△ △ △ and the comparison of blank group, p<0.001, with relatively ， ﹡ p<0.05 of model control group
﹡ ﹡ and model control group comparison, p<0.01
Above result shows, metformin hydrochloride tablet and model control group comparison, and blood glucose obviously reduces; Purple taro stem and leaf extract high dose group and model group comparison, blood glucose obviously reduces, and has obvious hypoglycemic activity, illustrates that purple taro stem and leaf extract has obvious hypoglycemic activity to alloxan being caused to diabetic mice hyperglycemia.
experimental example 4:
the purple taro bulb of the present invention extract causes the impact of diabetic mice hyperglycemia on alloxan
Experiment material
(1)animal: Kunming mouse, male, body weight 19～22g and 22-25, purchased from animal housing of Norman Bethune Medical University; The quality certification number is SCXK-(Ji) 2008-0005.
(2) medicine: purple taro bulb extract is provided by my institute's chemistry chamber.Metformin hydrochloride tablet is produced by Beijing JingFeng Pharmaceutical Co., Ltd.Lot number 20100718, blood sugar kit is by raw providing in Beijing, and lot number is respectively 201206 and 201107112671.
(3) dosage setting: sample proposes people and uses dosage 30g crude drug/70kg, mouse experiment is got the dose,equivalent of 8,4,2 times, 1g powder is equivalent to 16.0g crude drug, purple taro bulb extract mouse experiment is got the dose,equivalent of 16,8,4 times, bulb extract doses is 4.0,2.0,1.0g/kg, and metformin hydrochloride tablet is got the dose,equivalent 0.26g/kg group of people's consumption of 2 times.
(4) medicine preparation: press per kilogram 20 ml volumes preparations.Prepared by chemical chamber.
experimental technique and result
Get 100 of mices, be divided at random 5 groups, be respectively blank group, model control group, bulb extract is high, medium and low 4.0,2.0,1.0g/kg group, tail vein injection alloxan 80mg/kg/10ml, after 72 hours, eye socket is got blood, picks hypoglycemia value animal, evenly divide into groups by blood glucose value, the results are shown in Table 9.
Each group blood glucose value (mmol/L) after table 9 modeling type
﹡ ﹡ ﹡ and the comparison of blank group, model is set up, p<0.001
Get and make model mouse, each group is pressed the administration respectively of 20ml/kg volume, and blank and model group gavage equal-volume distilled water.Each group successive administration 10 days, hungry mice 16 hours before last administration, after last administration 40 minutes, pluck eyeball of mouse and get blood, survey blood glucose by glucose oxidase method with blood sugar kit.The results are shown in Table 10
Each group blood glucose value (mmol/L) after table 10 administration
| Group | Dosage g/kg | Blood glucose value |
| Blank group | ? | 7.93±2.14 |
| Model control group | ? | 21.53±4.62 |
| Bulb high dose | 4.0 | 18.45±4.41﹡ |
| Dosage in bulb | 2.0 | 19.31±6.38﹡ |
| Bulb low dosage | 1.0 | 17.98±3.16﹡ |
﹡ and model control group comparison, p<0.05
Above result shows purple taro bulb extract and model group comparison, and blood glucose obviously reduces, and has obvious hypoglycemic activity.
Prove that purple taro bulb extract causes that to alloxan diabetic mice hyperglycemia has obvious hypoglycemic activity.
the medical function of the purple taro extract of the present invention to type 2 diabetes mellitus volunteer
case 1
Certain man, 62 years old, type 2 diabetes mellitus history 5 years, by medicine control, fasting glucose is at 7-7.8 mmol/L.Within 2011, December starts to eat the purple taro stem and leaf extract of the present invention on the 1st, and every day 2 times, each 0.5g, takes original Western medicine every day as usual, within 5 days, finds afterwards that blood glucose obviously declines in the situation that diet does not change.After this eat continuously two weeks left and right, measure blood glucose every day, measured value is all in 6.5mmol/L left and right, and mensuration is many subsequently wherein has 2 times below 6 mmol/L below 6.5mmol/L, feels good.
case 2
Fourth, man, 49 years old, main suit was thirsty, polydipsia, weak more than 4 years, looks into fasting glucose 9.2mmol/L, glucose in urine +++ and be diagnosed as " diabetes ", take effect undesirable over 3 years through Chinese medicine and western medicine, period in a medicine blood glucose drops to 7.85mol/L left and right, and drug withdrawal rebounds.Take extract of the present invention, every day 2 times, each 1g, after January, fasting glucose is reduced to 5.3mol/L, and glucose in urine is normal.After take 1-2 time weekly, take after 2 months drug withdrawal half a year, before the meal, hematuria sugar is all normal after the meal.
case 3
Liu, female, suffers from diabetic history nearly 5 years in 55 years old, for a long time with Western medicine glucose-lowering treatment, due to the control that is not careful in one's diet at ordinary times, and complicated with diabetes foot, blood sugar increasing, Relapse rate, looking into fasting glucose is 9.3mmoi/l, diabetic foot is with lower limb pain.Patient takes extract of the present invention, and every day 2 times, each 3 grams, after two months, fasting glucose is down to 5.8mmoi/l, and the mental status is good, and the healing of diabetic foot part, has a pain in the leg and alleviate.Continue to take 2 months, state of an illness control is satisfied, and blood glucose is within normal range, and diabetes are almost recovered, existing continual cure.
case 4
Liao, man, 50 years old, suffer from diabetes 7 years, take the treatment of Western medicine antidiabetic drug, maintain blood glucose, but due to the control that is not careful in one's diet at ordinary times, emotional instability, poor effect, the state of an illness is serious day by day, and blood glucose is difficult to control, and has to adopt insulinize, take extract of the present invention through coordinating, every day 2 times, each 1.5 grams, " three-many-one-little " obviously disappears, after the course for the treatment of, stop Western medicine, continue pair and use this extract, 1 month, blood sugar recovery is normal, continue to strengthen again recovery from illness after two months, now drug withdrawal, no abnormality seen.
Claims (4)
1. purple taro and stem and leaf thereof the purposes in preparation treatment and prevent diabetes medicine.
2. treatment claimed in claim 1 and prevent diabetes medicine, is characterized in that the pharmaceutical composition that contains one or more pharmaceutically acceptable carriers or excipient.
3. a preparation method for purple taro and stem and leaf extract thereof, is characterized in that:
Get purple taro or its stem and leaf removes mud, add 2-10 times water gaging, boil; After ultra high temperature short time sterilization, adopt aseptic packaging technology to pack.
4. a preparation method for purple taro and stem and leaf extract thereof, is characterized in that:
Get purple taro or its stem and leaf removes mud, add 5-30 times water gaging or organic solvent, decoct or heating or reflux (1-4 time, 0.1-3 hour at every turn), get extracting solution reclaim under reduced pressure; Also can be further refining by methods such as precipitate with ethanol, obtain extract, make various preparations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310474691.4A CN103768294A (en) | 2013-10-12 | 2013-10-12 | Medical application of colocasia tonoimo nakia and stem leaves thereof in preventing and treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310474691.4A CN103768294A (en) | 2013-10-12 | 2013-10-12 | Medical application of colocasia tonoimo nakia and stem leaves thereof in preventing and treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103768294A true CN103768294A (en) | 2014-05-07 |
Family
ID=50561354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310474691.4A Pending CN103768294A (en) | 2013-10-12 | 2013-10-12 | Medical application of colocasia tonoimo nakia and stem leaves thereof in preventing and treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103768294A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112956562A (en) * | 2021-03-07 | 2021-06-15 | 常德集智生物科技有限公司 | Tea with weight-losing and lipid-lowering effects |
| CN115814007A (en) * | 2022-12-08 | 2023-03-21 | 中国医学科学院药用植物研究所云南分所 | Alpha-glucosidase inhibitor and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101690789A (en) * | 2009-09-29 | 2010-04-07 | 王德玉 | Chinese medicinal preparation for treating diabetes |
| CN102716416A (en) * | 2012-06-12 | 2012-10-10 | 陈世贤 | Traditional Chinese medicine composition for treating stomach diseases |
-
2013
- 2013-10-12 CN CN201310474691.4A patent/CN103768294A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101690789A (en) * | 2009-09-29 | 2010-04-07 | 王德玉 | Chinese medicinal preparation for treating diabetes |
| CN102716416A (en) * | 2012-06-12 | 2012-10-10 | 陈世贤 | Traditional Chinese medicine composition for treating stomach diseases |
Non-Patent Citations (4)
| Title |
|---|
| 世风: ""辨色食蔬菜巧防病"", 《晚晴》 * |
| 中国科学院中国植物志编辑委员会: "《中国植物志 第十三卷第二分册》", 30 September 1979, 科学出版社 * |
| 凌文华: ""花色苷"", 《中国营养学会DRIS修订专家委员会第二次会议样板稿汇编》 * |
| 王瑞兰等: ""紫芋花色苷的抗氧化活性及其稳定性研究"", 《怀化学院学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112956562A (en) * | 2021-03-07 | 2021-06-15 | 常德集智生物科技有限公司 | Tea with weight-losing and lipid-lowering effects |
| CN115814007A (en) * | 2022-12-08 | 2023-03-21 | 中国医学科学院药用植物研究所云南分所 | Alpha-glucosidase inhibitor and preparation method and application thereof |
| CN115814007B (en) * | 2022-12-08 | 2024-01-26 | 中国医学科学院药用植物研究所云南分所 | Alpha-glucosidase inhibitor and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102271698B (en) | Pharmaceutical composition and use for preparing medicament thereof | |
| CN103768294A (en) | Medical application of colocasia tonoimo nakia and stem leaves thereof in preventing and treating diabetes | |
| CN101744986B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
| CN107266599B (en) | Flammulina velutipes polysaccharide, extraction method and application thereof in preparation of medicine for treating functional constipation | |
| CN105832814A (en) | General flavone with effect of treating diabetic mellitus, as well as preparation method and application thereof | |
| CN101744993B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
| CN101744996B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN101745017B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN101745008B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN105287921A (en) | Medicinal composition for treating gastric cancer and preparation method thereof | |
| CN101120969A (en) | Medicine for treating diabetes and its complications and preparing method thereof | |
| CN104474103A (en) | Natural plant hypoglycemic agent and preparation method thereof | |
| CN104352748A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN103751255A (en) | Pachymaran composition for decreasing blood sugar and preparation method thereof | |
| CN101744990B (en) | Method for individually extracting ginseng, radix ophiopogonis and schisandra chinensis and preparation thereof | |
| CN101744999B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
| CN111803559B (en) | A kind of eggplant peel composition with hypoglycemic effect and preparation method and application thereof | |
| CN108143756A (en) | A kind of plant hypoglycemic agent and preparation method thereof | |
| CN101744994B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
| CN101745007B (en) | Extraction method of 'radix ophiopogonis/ginseng and schisandra chinensis' and preparation thereof | |
| CN101745006B (en) | Extraction method of ophiopogon root, ginseng and shiandra and preparation thereof | |
| CN101745001B (en) | Extraction method of ophiopogon root, ginseng and shiandra and preparation thereof | |
| CN101491581A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN101745011A (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN101744995B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140507 |